



Press release February 20, 2009

Insider trading in Diamyd Medical

Directors of the Board and senior executive have bought shares in Diamyd Medical.

Directors of the Board Henrik Bonde and Lars Jonsson have during Wednesday and Thursday respectively bought shares in Diamyd Medical. Lars Jonsson now owns 600 B-shares and Henrik Bonde 400 B-shares.

Resigning Chief Communications Officer Sonja Catani bought 1200 B-shares during Wednesday and now owns 1400 B-shares and 2000 warrants Diamyd TO 2B with strike price 100 SEK, exercise period ending April 17 2009.

For more information, please contact:

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.), elisabeth.lindner@diamyd.com
Phone: +46-8-661 00 26

This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.

Diamyd Medical is a Swedish biopharmaceutical company focusing on development of pharmaceuticals for treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd[®] for type 1 diabetes for which Phase III trials are ongoing in both the US and Europe. Furthermore, the company has started clinical studies within chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson's disease.

Diamyd Medical has offices in Sweden and in the US. The share is quoted on the OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's web site: www.diamyd.com.

Diamyd Medical AB (publ.)

Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68

E-mail: info@diamyd.com. VATno: SE556530-142001.

(www.omxnordicexchange.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)